In November 2023, the U.S. Food & Drug Administration approved two renal denervation systems for treating uncontrolled hypertension. Both systems use the same principal: By destroying nerves in the kidneys, they change the way the kidneys regulate blood pressure. Only the energy used to accomplish this task differs: The Paradise™ system uses ultrasound, and the Symplicity Spyral™ system utilizes radiofrequency energy.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to Heart Advisor
Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
